Regeneron Pharmaceuticals Inc. shares inched 0.16% higher to $503.23 Tuesday. This proved to be an all-around mixed trading session for the stock market, with the Dow Jones Industrial Average DJIA rising 0.13% to 34,575.31 and the S&P 500 Index SPX falling 0.05% to 4,202.04.
Regeneron Pharmaceuticals Inc. closed $161.41 short of its 52-week high ($664.64), which the company achieved on July 20th. The stock outperformed some of its competitors Tuesday, as Johnson & Johnson JNJ fell 2.20% to $165.53, Novartis AG ADR NVS fell 0.29% to $88.12, and Amgen Inc. AMGN fell 1.83% to $233.58. The trading volume (606,804) of Regeneron Pharmaceuticals Inc remained 212,168 below its 50-day average volume of 818,972. This stock maintains the consecutive two days gain.
The company reminded investors that in December 2020, America based Regeneron paused new enrollment of patients with B-cell non-Hodgkin lymphomas in studies as the FDA had put a partial clinical hold. The agency requested that the company amend the trial protocols to further reduce the incidence of ≥Grade 3 cytokine release syndrome during step-up dosing. The syndrome, which is caused by a large, rapid release of immune substances called cytokines, may occur after treatment with some types of cancer therapies and can sometimes be severe or fatal.